Trial Profile

A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin as a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved Interventions

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary) ; Candida antigen; Sodium chloride
Indications Ankylosing spondylitis; Atopic dermatitis; Discoid lupus erythematosus; Giant cell arteritis; Graves ophthalmopathy; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Lichen planus; Lupus nephritis; Necrobiosis lipoidica; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; SARS-CoV-2 acute respiratory disease; Spondylarthritis; Tendon injuries
Focus Adverse reactions
Sponsors Janssen Research & Development

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com